Exact Sciences Corporation (NASDAQ:EXAS) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 18,237,019 shares, a decline of 11.2% from the July 14th total of 20,541,875 shares. Based on an average trading volume of 2,797,106 shares, the short-interest ratio is presently 6.5 days. Approximately 15.7% of the shares of the stock are short sold.

Shares of Exact Sciences Corporation (EXAS) opened at 38.74 on Tuesday. The company has a 50-day moving average of $37.72 and a 200-day moving average of $29.14. The stock’s market capitalization is $4.61 billion. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $42.18.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. The business had revenue of $57.65 million during the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. Equities analysts expect that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $39.41, for a total transaction of $230,390.86. Following the completion of the sale, the chief financial officer now directly owns 19,861 shares in the company, valued at $782,722.01. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP D Scott Coward sold 1,987 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the sale, the senior vice president now owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The disclosure for this sale can be found here. Insiders own 4.00% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Fortaleza Asset Management Inc. bought a new stake in Exact Sciences Corporation during the second quarter worth about $106,000. Northwestern Mutual Wealth Management Co. raised its stake in Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after buying an additional 600 shares during the period. Financial Architects Inc raised its stake in Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after buying an additional 2,035 shares during the period. Johnson Financial Group Inc. raised its stake in Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after buying an additional 1,000 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Exact Sciences Corporation by 66.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock worth $179,000 after buying an additional 2,013 shares during the period. 85.44% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently commented on EXAS. Jefferies Group LLC reiterated a “buy” rating and set a $25.00 price target on shares of Exact Sciences Corporation in a report on Wednesday, April 26th. Cowen and Company lifted their price target on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Monday, May 15th. Leerink Swann set a $38.00 price target on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a report on Friday, April 28th. Vetr downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 price target for the company. in a report on Thursday, July 6th. Finally, Roth Capital reiterated a “buy” rating and set a $40.00 price target (up from $33.00) on shares of Exact Sciences Corporation in a report on Thursday, June 1st. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Exact Sciences Corporation presently has a consensus rating of “Buy” and an average price target of $40.51.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/15/exact-sciences-corporation-nasdaqexas-short-interest-update.html.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.